Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
PathAI logo — Improving patient outcomes with AI-powered pathology.

PathAI

Improving patient outcomes with AI-powered pathology.

Founded 2016 United States Boston, United States 277 employees Debt Financing Total: $355.20M Biotechnology, Health Care

General Information

Company Name PathAI
Founded Year 2016
Location United States Boston, United States
Founders / Decision Makers
Team member
Employees 277
Industries Biotechnology, Health Care
Funding Stage Debt Financing
Business Model B2B, SaaS, Platform
Revenue Model Subscription, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with PathAI. To contact PathAI, visit pathai.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does PathAI compare?

A PDF of PathAI and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting PathAI soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Nov 05, 2026

PathAI representatives reflected on their participation and conversations at the ESMO conference in Madrid.

Regulatory Approval Nov 05, 2026

PathAI's AIM-MASH AI Assist is qualified by the FDA and EMA for histology enrollment and endpoint assessment.

New Partnership Nov 05, 2026

PathAI announced a scientific program partnership with Akero Therapeutics for an oral presentation at #TLM26.

PathAI a competitor of yours? Have our desk watch it

About PathAI

PathAI, founded in 2016, is carving a niche in the Biotechnology and Health Care sectors by focusing on AI-enhanced pathology. Their slogan, "Improving patient outcomes with AI-powered pathology," encapsulates their mission to leverage machine learning to enhance diagnostic accuracy and treatment efficacy, particularly in complex diseases such as cancer.

Benefitting from a strong, diverse team passionate about impactful problem-solving, PathAI also enjoys a strategic location in Fenway, United States, adding to its appeal as a workplace, highlighted by its recent accolade as one of BBJ's Best Places to Work.

The company's latest financial milestone was a $100.00M debt financing investment received on 01 January 2022. As the pathology market expands and technological advancements continue to transform healthcare, PathAI's innovative model presents a compelling case for stakeholders looking at long-term value in AI-driven healthcare solutions.

Business keywords: AI-Powered Pathology, Digital Pathology, Oncology, Immuno-Oncology, Neurodegenerative Disease, Companion Diagnostics, Precision Medicine, Computational Pathology, Deep Learning, Clinical Research Organization (CRO), Drug Development, HealthTech, Software Engineering, Cancer Research

Services & Products

AI-Powered Pathology Solutions
Digital Pathology Platform AISight®
Translational Research Services
Clinical Development Services
Real-World Data Analysis
Companion Diagnostics Development
Biomarker Quantification

Target Customers

Biopharma Companies Academic Medical Centers Reference Laboratories Health Systems Pathology Laboratories

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing $100.00M -
01 Jan 2022
Series C $165.00M 9
D1 Capital Partners General Atlantic KdT Ventures
D1 Capital Partners, General Atlantic +7
18 May 2021
Series B $15.00M 3
LabCorp
LabCorp, Merck Global Health Innovation Fund +1
04 Nov 2019
Series B $60.00M 3
General Atlantic General Catalyst Innospark Ventures
General Atlantic, General Catalyst +1
17 Apr 2019
Series A $11.00M 6
Pillar 8VC KdT Ventures
Pillar, 8VC +4
03 Nov 2017
Seed Round $4.20M 5
Pillar 8VC Fairhaven Capital
Pillar, 8VC +3
06 Dec 2016

Latest News

View All
FDA approved AI device that predicts cancer prognosis — Qz.com
FDA approved AI device that predicts cancer prognosis
Qz.com Nov 23, 2025

PathAI Alternatives & Competitors

View All Alternatives
PathAI vs
Nilogen Oncosystems
Nilogen Oncosystems United States

We analyze cancer drug responses using fresh patient tumor tissue with intact tumor microenvironment...

17 employees
Biotechnology, Health Care
Compare PathAI vs Nilogen Oncosystems
PathAI vs
Ibex Medical Analytics
Ibex Medical Analytics United States

Pioneering AI-based cancer diagnostics in pathology

Series C
95 employees
AI, Analytics
Compare PathAI vs Ibex Medical Analytics
PathAI vs
Oxford BioTherapeutics
Oxford BioTherapeutics United Kingdom

Redefining the cancer-immune synapse for novel immune checkpoint mechanisms

66 employees
Biotechnology, Health Care
View all alternatives

FAQ About PathAI

Improving patient outcomes with AI-powered pathology.
PathAI was founded in 2016.
PathAI is headquartered in Boston, United States.
PathAI operates in Biotechnology and Health Care. Its work centres on AI-Powered Pathology, Digital Pathology, Oncology and Immuno-Oncology. Its customers include Biopharma Companies, Academic Medical Centers and Reference Laboratories.
PathAI has a B2B, SaaS and Platform business model. Its revenue comes from Subscription, Licensing and Service Fee.
PathAI has approximately 277 employees.
PathAI has completed 6 funding rounds, raising a total of $355.20M. The latest funding stage is Debt Financing.
PathAI offers: AI-Powered Pathology Solutions, Digital Pathology Platform AISight®, Translational Research Services, Clinical Development Services, Real-World Data Analysis, Companion Diagnostics Development, Biomarker Quantification.
Top alternatives and competitors to PathAI include Nilogen Oncosystems, Ibex Medical Analytics, Oxford BioTherapeutics, Celsius Therapeutics, radiomics.bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PathAI and Nilogen Oncosystems are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for PathAI, https://bouncewatch.com/company/pathai, updated 5 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout